Video

The Future of AI in Drug Discovery: How Artificial Intelligence is Generating Ideas for New Medicines

In this latest podcast episode from The Future Labs, Dr Jackie Hunter, our Board Director at BenevolentAI, explores how artificial intelligence is generating new ideas for new medicines, and cutting the time and cost of designing drugs to bring them to patients faster.

The development of new drugs and treatments is an extremely complicated and failure-prone process. As an example of the scale of the challenge - developing a drug and getting it to market can take 10-15 years and cost more than $2.5 billion. What’s more, the top selling drugs available today only work for 30-50% of the patients to whom they are prescribed.

Although technology has been an indispensable component of drug discovery for decades, patients are not yet authentically benefiting from its potential at it relates to the generation of  new and more effective treatments.

In this podcast, Jackie discuss how the high cost and decline in tangible outputs from drug R&D, has resulted in the need to seek out new inventive solutions to improve the efficiency of medicinal development. We explore a radically different approach - how building machine learning tools and applying artificial intelligence to drug discovery can create new ideas to be interpreted by scientists in the lab.

Listen to Jackie explain BenevolentAI’s approach to drug discovery and the progress we are making to better understand diseases and to develop treatments for the millions of patients that need them.

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022